Category Archives: Brust und Gynäkologie

1. ESMOupdate 2012, Breast and Gynecological Cancers

Prof. Dr. med. Monica Castiglione und Dr. med. Daniel Helbling besprechen die wichtigsten, klinisch relevanten Studien im Bereich Breast and Gynecological Cancer, die am diesjährigen ESMO (European Society for Medical Onocology) Meeting in Wien präsentiert wurden.

Diskutierte Studien:
LBA6_PR: HERA TRIAL: 2 years versus 1 year of trastuzumab after adjuvant chemotherapy in women with HER2-positive early breast cancer at 8 years of median follow up; A. Goldhirsch et al

LBA12: Updated Overall Survival Results from EMILIA, a phase 3 study of trastuzumab emtansine (T-DM1) vs capecitabine (X) and lapatinib (L) in HER2-positive locally advanced or metastatic breast cancer (MBC); S. Verma et al

4. ASCOupdate 2011, Brust- und gynäkologische Tumore

Diskussionsleiter Dr. A. Müller, Kantonsspital Winterthur, bespricht folgende Studien:

Abstract LBA 504: Exemestane for primary prevention of breast cancer in postmenopausal women: NCIC CTG MAP.3-A randomized placebo-controlled clinical trial

Abstract 509: LANDSCAPE: An FNCLCC phase II study with lapatinib (L) and capecitabine (C) in patients with brain metastases (BM) from HER2-positive metastatic breast cancer (MBC) before whole brain radiotherapy (WBR)

Abstract LBA1003: NCIC-CTG MA.20: An intergroup trial of regional nodal irradiation in early breast cancer

Abstract 1007: A randomized phase III study of iniparib (BSI-201) in combination with gemcitabine/carboplatin (G/C) in metastatic triple-negative breast cancer (TNBC)

Abstract LBA5006: Result of interim analysis of overall survival in the GCIG ICON7 phase III randomised trial of bevacizumab in women with newly diagnosed ovarian cancer

Abstract LBA5007: OCEANS: A randomized, double-blinded, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab (BEV) in patients with platinumsensitive recurrent epithelial ovarian(EOC), primary peritoneal (PPC), or fallopian tube cancer (FTC)